Well, there are 1.1 million hiv positive people on the us alone. There are 1.8 million cases of cancer diagnosed per year in the us and the estimate is for about 12% of the us population to develop NASH. I’m not saying all of these people will be candidates for leronlimab but even if only 10% do, the revenue is huge. $100/share is very realistic in a simple math methods. What is really difficult to calculate is how this is at $.30.